Revenue
2018
2019
2020
2021
2022
2023
2024
2025
ADC Therapeutics SA (ADCT)
Price$1.34Cached quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $81.4M | $70.8M | $69.1M | $209.9M | $33.9M | $0 | $2.3M | $1.1M |
| Gross profit | $75.6M | $64.9M | $66.5M | $205.3M | $32.5M | $0 | $2.3M | — |
| Gross margin | 92.87% | 91.60% | 96.34% | 97.82% | 95.89% | — | 100.00% | — |
| Research & development | $104.0M | $109.6M | $127.1M | $187.9M | $158.0M | $142.0M | $107.5M | $118.3M |
| Operating expenses | $202.9M | $201.5M | $235.5M | $333.3M | $295.6M | $219.3M | $121.7M | $127.1M |
| Operating income | −$121.5M | −$130.7M | −$166.0M | −$123.6M | −$261.7M | −$219.3M | −$119.4M | −$125.9M |
| Operating margin | −149.34% | −184.44% | −240.35% | −58.90% | −771.65% | — | −5,102.52% | −11,047.46% |
| EBITDA | −$120.8M | −$129.3M | −$164.8M | −$122.6M | −$260.8M | −$218.5M | −$118.8M | −$125.5M |
| EBITDA margin | −148.47% | −182.56% | −238.63% | −58.41% | −768.94% | — | −5,078.93% | −11,004.65% |
| Net income | −$142.6M | −$157.8M | −$240.1M | −$155.8M | −$230.0M | −$246.3M | −$116.5M | −$123.1M |
| Net profit margin | −175.31% | −222.83% | −347.60% | −74.22% | −678.20% | — | −4,977.95% | −10,797.89% |
| Basic EPSper basic share | -$1.12 | -$1.62 | -$2.94 | -$1.99 | -$3.00 | -$3.77 | -$2.36 | -$2.64 |
| Diluted EPSper diluted share | -$1.12 | -$1.62 | -$2.94 | -$2.01 | — | -$3.77 | -$2.36 | -$2.64 |
Owners
Reported shareholders
19.34%of listed shares
Nantahala Capital Management, LLC24.65M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Nantahala Capital Management, LLC | 19.34%24.65M shares |
Redmile Group, LLC | 9.04%11.53M shares |
TCG Crossover Management, LLC | 8.94%11.39M shares |
WILD HANS PETER | ≈7.68%9.79M shares |
Prosight Management, LP | 6.14%7.82M shares |
BlackRock, Inc. | 5.51%7.02M shares |
Point72 Asset Management, L.P. | 2.86%3.65M shares |
MORGAN STANLEY | 2.39%3.05M shares |
MILLENNIUM MANAGEMENT LLC | 2.28%2.9M shares |
MALLIK AMEET | ≈1.66%2.12M shares |
CITADEL ADVISORS LLC | 1.61%2.05M shares |
GOLDMAN SACHS GROUP INC | 1.50%1.91M shares |
STATE STREET CORP | 1.32%1.69M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.13%1.45M shares |
BANK OF AMERICA CORP /DE/ | 1.01%1.29M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 0.70%897.09K shares |
TWO SIGMA INVESTMENTS, LP | 0.61%773.41K shares |
Carmona Jose | ≈0.58%734.38K shares |
Blue Owl Capital Holdings LP | 0.58%733.57K shares |
D. E. Shaw & Co., Inc. | 0.56%719.32K shares |
Percentages use 127.44M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 2, 2026Form 4 | RedCo II Master Fund, L.P. +2TenPercentOwner | SellCommon Stock | 2.53M | $3.28 | $8.30M | 10.27M |
| Apr 2, 2026Form 4 | RedCo II Master Fund, L.P. +2TenPercentOwner | SellCommon Stock · indirect | 2.63M | $3.28 | $8.64M | 12.67M |
| Apr 1, 2026Form 4 | RedCo II Master Fund, L.P. +2TenPercentOwner | SellCommon Stock | 162.5K | $3.80 | $617.6K | 12.79M |
| Apr 1, 2026Form 4 | RedCo II Master Fund, L.P. +2TenPercentOwner | SellCommon Stock · indirect | 169.3K | $3.80 | $643.2K | 15.30M |
| Mar 31, 2026Form 4 | RedCo II Master Fund, L.P. +2TenPercentOwner | SellCommon Stock | 188.4K | $3.75 | $706.5K | 12.96M |